Cellbricks Therapeutics
Cellbricks Therapeutics
Biofabrication platform for 3D-printed human tissue implants and future organ manufacturing.
About
What does Cellbricks Therapeutics do?
Cellbricks Therapeutics is a Berlin-founded biotech startup focused on developing a proprietary biofabrication platform for creating vascularized human tissue implants. Their technology combines human cells with biomaterials to produce tissue constructs for implantation, initially targeting soft tissue loss, complex wounds, and reconstructive defects. The company's long-term vision is to build the capabilities for manufacturing fully functional, implantable human organs. Their platform utilizes…
What is Cellbricks Therapeutics's revenue?
StartupHub estimates Cellbricks Therapeutics's annual revenue at $573K (range $164K to $2.3M, 34% confidence), based on comparable companies in the sector.
What is Cellbricks Therapeutics's valuation?
StartupHub estimates Cellbricks Therapeutics's effective valuation at $28.4M (range $17.5M to $42.0M, 23% confidence), based on comparable companies in the sector.
How much funding has Cellbricks Therapeutics raised?
Cellbricks Therapeutics has raised a total of $7M in funding. The most recent round on record is Seed.
Where is Cellbricks Therapeutics headquartered?
Cellbricks Therapeutics is headquartered in Berlin, Germany.
What industry does Cellbricks Therapeutics operate in?
Cellbricks Therapeutics operates in Biotechnology, Medical Devices, Regenerative Medicine, 3D Printing.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Develops and commercializes treatments for central nervous system disorders, including Rett syndrome.
A deep-tech company developing nanorobotic solutions for healthcare, initially targeting dental care applications.
MatrixCode is a research focus at the Freiburg Institute for Advanced Studies (FRIAS) investigating matrisome pathology.
A company focused on privacy, Zcash accumulation, and developing cancer therapeutics.
An entrant is a company tagged Biotechnology whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.